Stock Analiz

Iovance Biotherapeutics, Inc. (IOVA) financials: revenue, earnings and cash flow

Fiscal 2016–2025 + TTM · from SEC filings · data as of November 16, 2026

Summary

Net income in fiscal 2025 was -$391M, a net margin of -148.4%; the best year in this period was 2016 with -$53M.

Over the twelve months to September 30, 2026, revenue was $379M and net income -$221M.

Free cash flow was -$336M in fiscal 2025 and positive in 0 of the 10 years shown.

The diluted share count rose 547% over the period (dilution).

Revenue, profit and cash flow by year

Revenue
2016: $020162017: $020172018: $020182023: $1M20232024: $164M20242025: $264M2025$264M
Net income
2016: -$53M162017: -$92M172018: -$124M182019: -$198M192020: -$260M202021: -$342M212022: -$396M222023: -$444M232024: -$372M242025: -$391M25-$391M
Free cash flow
2016: -$34M162017: -$80M172018: -$102M182019: -$166M192020: -$252M202021: -$266M212022: -$313M222023: -$384M232024: -$364M242025: -$336M25-$336M
EPS (diluted)
2016: $-1.85162017: $-1.41172018: $-1.27182019: $-1.59192020: $-1.88202021: $-2.23212022: $-2.49222023: $-1.89232024: $-1.28242025: $-1.0925$-1.09

Income statement

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$379M$264M$164M$1M————$0$0$0
Gross profit$202M$90M$71M$156000———————
Operating income-$230M-$403M-$395M-$461M-$399M-$343M-$262M-$207M-$128M-$93M-$54M
Net income-$221M-$391M-$372M-$444M-$396M-$342M-$260M-$198M-$124M-$92M-$53M
EPS (diluted)$-0.50$-1.09$-1.28$-1.89$-2.49$-2.23$-1.88$-1.59$-1.27$-1.41$-1.85
R&D$242M$300M$276M$333M$295M$259M$202M$166M$100M$72M$27M
Revenue growth—+60.6%+13699.0%————————

Cash flow

Fiscal yearTTM2025202420232022202120202019201820172016
Operating cash flow-$190M-$302M-$353M-$362M-$293M-$228M-$205M-$159M-$101M-$79M-$33M
Capital spending-$26M-$34M-$11M-$22M-$20M-$38M-$47M-$7M-$1M-$1M-$2M
Free cash flow-$216M-$336M-$364M-$384M-$313M-$266M-$252M-$166M-$102M-$80M-$34M
Dividends paid—$0$0$0$0$0$0$0$0$0$0
Buybacks———————————
Stock-based pay$47M$62M$110M$63M$84M$70M$41M$24M$20M$12M$19M

Balance sheet

Fiscal yearTTM2025202420232022202120202019201820172016
Cash—$297M$324M$280M$472M$504M$629M$307M$469M$145M$107M
Debt—$49M$58M$76M$85M$72M$52M$12M———
Equity—$699M$710M$585M$500M$622M$656M$299M$466M$145M$167M
Total assets—$913M$910M$780M$664M$777M$768M$345M$481M$155M$172M
Shares (diluted)434M0M0M0M0M0M0M0M0M0M0M

Margins and returns

Fiscal yearTTM2025202420232022202120202019201820172016
Gross margin53.2%34.3%43.2%13.1%———————
Operating margin-60.8%-153.1%-240.9%-38735.0%———————
Net margin-58.2%-148.4%-226.8%-37345.4%———————
FCF margin-57.0%-127.6%-221.9%-32305.3%———————
ROIC—-53.6%-51.0%-69.2%-68.2%-49.4%-29.2%-52.6%-21.7%-50.4%-25.4%
ROE—-56.0%-52.4%-75.9%-79.2%-55.0%-39.5%-66.1%-26.5%-63.3%-31.7%

Frequently asked questions

What is Iovance Biotherapeutics’s annual revenue?

$264M in fiscal 2025 and $379M over the twelve months to September 30, 2026.

How much profit does Iovance Biotherapeutics make?

Net income was -$391M in fiscal 2025 (net margin -148.4%).

Is Iovance Biotherapeutics’s revenue growing?

Yes: revenue rose 60.6% in fiscal 2025 compared with the year before.

From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.